These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 37876726)

  • 21. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
    García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
    J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study.
    Hajjat TM; Mosha M; Whaley KG; Rosen MJ; Suppa C; Markowitz J; Dufour L; Sauer C; Shukla-Udawatta M; Boyle B; Gibson M; Shapiro J; Sams D; Sylvester F; Hunter G; Perez ME; Hyams JS
    Crohns Colitis 360; 2021 Jul; 3(3):otab039. PubMed ID: 36776669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
    J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
    Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
    BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.
    Wilson M; Lucas A; Cameron A; Luo M
    Am Health Drug Benefits; 2018 Jul; 11(5):253-262. PubMed ID: 30464793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
    Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study.
    Yang H; Huang Z; Li M; Zhang H; Fu L; Wang X; Yang Q; He Y; Wu W; Jiang T; Sun Z; Zhang T; Lai D; Wu X; Shi L; Guo Q; Wu Y; Tang J; Chao K; Gao X
    EClinicalMedicine; 2023 Dec; 66():102337. PubMed ID: 38089859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Onali S; Pugliese D; Caprioli FA; Orlando A; Biancone L; Nardone OM; Imperatore N; Fiorino G; Cappello M; Viola A; Principi MB; Bezzio C; Aratari A; Carparelli S; Mazzuoli S; Manguso F; Grossi L; Bodini G; Ribaldone D; Mocci G; Miranda A; Minerba L; Favale A; Grova M; Scucchi L; Segato S; Fries W; Castiglione F; Armuzzi A; Fantini MC;
    Am J Gastroenterol; 2022 Aug; 117(8):1279-1287. PubMed ID: 35467558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A; Al Lehaibi LH; Alomar M; Aldhuwayan F; Alshouish S; Al-Ali AY; Almudhry Z; Almulhim A; Althagafi A; Aldosari S; AlAmeel T
    Saudi J Gastroenterol; 2024 Sep; 30(5):324-334. PubMed ID: 39157885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A
    Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.
    Kim MJ; Kim YJ; Jeong D; Kim S; Hong S; Park SH; Jo KW
    Therap Adv Gastroenterol; 2024; 17():17562848241265013. PubMed ID: 39092170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.
    De Vos M; Dhooghe B; Vermeire S; Louis E; Mana F; Elewaut A; Bossuyt P; Baert F; Reenaers C; Van Gossum M; Macken E; Ferrante M; Hindryckx P; Dewit O; Holvoet T; Franchimont D;
    United European Gastroenterol J; 2018 Apr; 6(3):439-445. PubMed ID: 29774158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.